Cipla Gets CGT Nod For US Migranal Rival
FDA Approval With CGT Designation Comes With 180-Day Exclusivity
Cipla’s generic equivalent of Migranal is the company’s first nasal spray to receive FDA approval, accompanied by 180 days of competitive generic therapy exclusivity.
